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Abstract
Background: Concerns about the general psychological impact of genetic testing have been raised. In the 
Environmental Triggers of Type 1 Diabetes (MIDIA) study, genetic testing was performed for HLA-conferred type 1 
diabetes susceptibility among Norwegian newborns. The present study assessed whether mothers of children who 
test positively suffer from poorer mental health and well-being after receiving genetic risk information about their 
children.
Methods: The study was based on questionnaire data from the Norwegian Mother and Child Cohort (MoBa) study 
conducted by the Norwegian Institute of Public Health. Many of the mothers in the MoBa study also took part in the 
MIDIA study, in which their newborn children were tested for HLA-conferred genetic susceptibility for type 1 diabetes. 
We used MoBa questionnaire data from the 30th week of pregnancy (baseline) and 6 months post-partum (3-3.5 
months after disclosure of test results). We measured maternal symptoms of anxiety and depression (SCL-8), maternal 
self-esteem (RSES), and satisfaction with life (SWLS). The mothers also reported whether they were seriously worried 
about their child 6 months post-partum. We compared questionnaire data from mothers who had received 
information about having a newborn with high genetic risk for type 1 diabetes (N = 166) with data from mothers who 
were informed that their baby did not have a high-risk genotype (N = 7224). The association between genetic risk 
information and maternal mental health was analysed using multiple linear regression analysis, controlling for baseline 
mental health scores.
Results: Information on genetic risk in newborns was found to have no significant impact on maternal symptoms of 
anxiety and depression (p = 0.9), self-esteem (p = 0.2), satisfaction with life (p = 0.2), or serious worry about their child 
(OR = 0.98, 95% CI 0.64-1.48). Mental health before birth was strongly associated with mental health after birth. In 
addition, an increased risk of maternal worry was found if the mother herself had type 1 diabetes (OR = 2.39, 95% CI 1.2-
4.78).
Conclusions: This study did not find evidence supporting the notion that genetic risk information about newborns 
has a negative impact on the mental health of Norwegian mothers.
Background
Predictive genetic testing is available for a range of dis-
eases, from single gene diseases, such as Huntington's
disease and cystic fibrosis, to multi-factorial diseases,
such as type 1 diabetes, hereditary cancers, and familial
hypercholesterolemia.
Type 1 diabetes is a complex disease for which impor-
tant genetic components have been identified. A specific
combination of the HLA class II genes (HLA-
DRB1*0401-DQA1*03-DQB1*0302/DRB1*03-DQA1*05-
DQB1*02) will give those who carry this genotype a 20%
lifetime risk for developing type 1 diabetes [1-5]. In the
E n v i r o n m e n t a l  T r i g g e r s  o f  T y p e  1  D i a b e t e s  ( M I D I A )
study Norwegian newborns carrying this high-risk geno-
type were identified and followed in a quest to identify
the environmental factors of the disease [6,7]. In the Nor-
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wegian population, 2.1% of newborns have this genotype,
and this group represents approximately 34% of future
cases of type 1 diabetes [5].
Several other studies have used predictive genetic test-
ing of newborns as a strategy to solve research questions
about environmental factors contributing to type 1 diabe-
tes, including DIPP in Finland [8], PANDA in Florida
[9,10], DiPiS in Sweden [11], DAISY in Colorado [12],
and the multinational TEDDY study in the USA and
Europe [13-15]. The main advantage for study partici-
pants identified as high-risk individuals is the possibility
of early detection of the destruction of the insulin pro-
ducing cells by autoantibodies, resulting in a milder dis-
ease onset [16], and the possibility of being the first to
participate in intervention studies when possible preven-
tive agents get available. However, there may be disadvan-
tages of living with the knowledge of an increased
susceptibility to a disease with no known prevention.
Thus, even though predictive testing is highly acknowl-
edged as a valuable research method per se, the predic-
tive testing of children has given rise to concerned debate
[17-19]. In an article about ethics, Ross concluded that, if
the research does not incorporate a prevention strategy,
studies involving predictive genetic testing of newborns
should avoid disclosing test results to minimize the harm
to infants and their families [18].
With the widespread and increasing use of genetic
tests, assessing the adverse effects of information about
susceptibility genes for disease on the tested subjects is
important. Our study aimed to estimate the effect on
maternal mental health from receiving genetic risk infor-
mation about their newborns. Outcome measures were
maternal self-report scores of anxiety and depression
symptoms, satisfaction with life, self-esteem, and serious
worry about the child. A number of previous studies [20-
24] have examined maternal reactions after being
informed that their children have an elevated genetic risk
for type 1 diabetes. None of these studies have shown a
significant effect on symptoms of anxiety or other mental
health disorders as a result of the testing, though a few
mothers did seem to react strongly. Previous studies were
conducted in a setting in which the mothers were asked
questions about how they felt in connection with the
genetic testing project. The present study was designed
differently. When completing the questionnaire, the
mothers were not aware that their answers were going to
be used for any particular comparisons, though they were
rightfully informed that the personal data would be used
for multiple research purposes. Thus, our results were
not affected by reporting bias associated with maternal
attitudes towards genetic risk information or other fac-
tors motivating the mothers to under- or over-report
poor mental health.
In the present study, information about mental health is
reported twice: before and after the mothers received the
information about genetic risk. These data permit us to
a n s w e r  o u r  m a i n  r e s e a r c h  q u e s t i o n  o f  t o  w h a t  e x t e n t
receiving information about a young child having an
increased risk of type 1 diabetes changes maternal well-
being and mental health.
Methods
Study design
This study was based on questionnaire data from the
Norwegian Mother and Child Cohort (MoBa) study
[25,26], an ongoing longitudinal study of the general
health and well-being of mothers and their children,
starting during pregnancy. A subgroup of the mothers in
the MoBa study participated in the MIDIA study (Envi-
ronmental Triggers of Type 1 Diabetes) [6,7] as well. In
MIDIA, the newborn child was tested for HLA-conferred
genetic susceptibility to type 1 diabetes. Questionnaire
data from the MoBa study were retrieved and used for the
analysis of mental health measures for mothers whose
children were genotyped in the MIDIA study. MoBa
questionnaire data from the 30th week of pregnancy ("the
30th week questionnaire") and 6 months post-partum (3-
3.5 months after disclosure of test results, "the 6 month
questionnaire") were used for the analysis.
Recruitment
The MoBa study was conducted by the Norwegian Insti-
tute of Public Health [26]. In brief, MoBa is a cohort con-
sisting of more than 100 000 pregnancies recruited
between 1999 and 2008. The majority of all pregnant
women in Norway were invited to participate, and the
participation rate was approximately 44%. Participants
were recruited for the study by postal invitation in con-
nection with being invited to a routine ultrasound exami-
nation offered to all pregnant women in Norway at 17-18
weeks of gestation http://www.fhi.no/morogbarn.
Informed consent was obtained from each participant
before inclusion in the study, which was approved by the
Regional Committee for Medical Research and the Nor-
wegian Data Inspectorate. The current study is based on
version 3 of the quality-assured data files released for
research in 2007. Information from the Medical Birth
Registry of Norway (MBRN) is also included in the data-
set [27].
The MIDIA study is a longitudinal prospective study in
which newborns from the general Norwegian population
carrying the high-risk HLA-DRB1*0401-DQA1*03-
DQB1*0302/DRB1*03-DQA1*05-DQB1*02 genotype
were identified and followed for the development of islet
autoantibodies and the onset of type 1 diabetes [6,7].
Approximately 50% of the children tested in MIDIA haveAas et al. BMC Medical Genetics 2010, 11:112
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mothers who also participated in MoBa. Recruitment for
the MIDIA study, which started in 2001, was described in
detail by Stene et al. [7]. All health care nurses across
Norway who took part in the recruitment, were trained
to give correct information about the project. Informed
consent was obtained from each participant before inclu-
sion in the study, which was approved by the Regional
Committee for Medical Research and the Norwegian
Data Inspectorate.
Study participants
The mothers included in this study delivered between
2001 and 2006, with the majority of deliveries in 2005
(37%). The study initially included 9762 mothers who had
their child genotyped in MIDIA and, at the same time,
participated in the MoBa study. Of these mothers, 7801
returned both the baseline (30th week of gestation) and
follow-up questionnaires (6 months post-partum). We
excluded 411 pregnancies of women with more than one
child. In most cases the first pregnancy or the first twin
was included. In six cases the older sibling was excluded
and the youngest included because the younger sibling
was a high-risk child. A total of 7390 eligible participants
were left for analysis.
Procedure for communicating genotype results in the 
MIDIA study
Information to parents of children with the high-risk 
genotype
The high-risk genotype information was conveyed to the
parents first by an initial phone call from one of four
health care workers on the MIDIA project. The informa-
tion provided during the phone call followed a semi-
structural scheme to ensure that important topics were
correctly communicated, including how to understand
the test results. They were also told that the genes were
inherited from both the mother and the father. The par-
ents were informed that they would receive a letter a few
days later with much of the same information in written
form. In the letter, the risk was explained with the word-
ing: "Children with the 'diabetes risk genes' have a 20%
lifetime risk of developing diabetes (one of five) and a 7%
risk of developing diabetes by the age of 15 years (1 of 17
children)." All parents were told that they were welcome
to call the project if they had more questions or were
worried about aspects related to the increased genetic
risk. After 1-2 weeks, the parents received a second
phone call with the purpose of clarifying unanswered
questions and providing additional information if
needed. In addition, all questionnaires received in the
MIDIA study were scrutinized by one of the nurses to
detect negative reactions due to the risk notification and
to become aware of mothers or fathers who were thinking
about their child's high genetic risk for type 1 diabetes
daily. If such signs were found, the parents were con-
tacted by phone. The term "diabetes risk genes" was used
in all communication with the parents, whereas the per-
haps more frightening term "high-risk genes" was
avoided.
Information to parents of children without the high-risk 
genotype
The parents of children without the high-risk genotype
were informed by letter. The letter stated that their child
did not have the diabetes risk genes, but it also informed
the parents that children without these genes can develop
type 1 diabetes. These children were not offered further
follow-up.
Follow-up of children with high genetic risk in the MIDIA 
study
It is of relevance for the present study, how the children
were followed-up between the high risk information was
provided and until 6 months of age. Follow-up after 6
months is described in Stene et al. [7]. When the high-
risk-children in the MIDIA study were 3 months old,
their parents received a package with a questionnaire.
The package also included equipment for a blood sample
to be taken at the health care clinic, and equipment for
stool samples to be collected from the diaper when the
child was 3, 4 and 5 months old [7]. The parents were told
that they would be notified if their child's blood samples
showed elevated levels of islet autoantibodies. A similar
package was received when the child was 6 months old.
The 6 month follow-up package was sent to the parents
approximately 2 weeks prior to the child turning 6
months old.
Questionnaire variables
In the MoBa study, the questions concerning mental
health were part of the questionnaire completed during
the 17th and 30th week of pregnancy and when the child
was 6 months, 18 months, and 3 years old. The present
study used data from the 30th week of pregnancy and 6
month questionnaires (Additional file 1 and Additional
file 2). The 6 month questionnaire from the MoBa study
was sent to the parents the same week as the child
became 6 months old.
Maternal symptoms of anxiety and depression: SCL-8
Maternal symptoms of anxiety and depression were
assessed using a short version of the SCL-25 [28]. The
short version, SCL-8, consists of eight items: four items
measuring depression and four items measuring anxiety.
The correlation between SCL-8 and SCL-25 is 0.94 [29].
Shorter versions of SCL-25 have been found to perform
almost as well as the full version when measuring anxiety
and depression [30,31]. SCL-8 has been demonstrated to
have an internal consistency of α = 0.88 [29].Aas et al. BMC Medical Genetics 2010, 11:112
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A global SCL-8 score was calculated as a sum of the
eight item scores. As the distribution of the total SCL-8
scores was positively skewed, a natural log transforma-
tion [ln(sum score)] was applied to the scores in order to
approximate a normal distribution. The skewness was
reduced from 2.6 to 1.2 and kurtosis from 10.3 to 1.2 for
the SCL-8 variable at 6 months. The baseline SCL-8 vari-
able was also transformed using the natural logarithm
(ln). Cronbach's alpha (internal consistency) in the pres-
ent sample was 0.83 for SCL-8.
The satisfaction with life scale
The five-item Satisfaction With Life Scale (SWLS) [32]
was developed to measure the cognitive component of
subjective well-being. In the original validation study
[32], the SWLS demonstrated an internal consistency of α
= 0.87. The instrument was calculated as a sum of the five
individual item scores. Cronbach's alpha in the present
data set was 0.88 for SWLS.
Rosenberg self-esteem scale
The short-form of the Rosenberg Self-Esteem Scale
(RSES) [33] used in the MoBa study includes four items.
These four items had a 0.95 correlation with the original
ten item scale and an internal consistency of α = 0.80 [29].
The instrument was calculated as a sum of the four indi-
vidual item scores (inverting the scores from the two
middle questions). Cronbach's alpha in the present sam-
ple was 0.78 for RSES.
Maternal worry about the child
Maternal worry about the child was one of the items in an
11-item checklist of life events experienced during the
last year, given in the 6 month questionnaire. The ques-
tion was phrased 'Have you been seriously worried that
there is something wrong with your child?' Responses
were coded as 'yes' or 'no'.
Maternal diabetes status
A dichotomous variable was constructed to indicate the
presence of maternal type 1 diabetes. The variable was
based on health questions from both the MBRN [27] and
the MoBa questionnaires. The mothers' own answers
from the MoBa study were used to supplement and, if
contradictory, correct the MBRN records. The agreement
between questionnaire data and MBRN records was
assessed as κ = 0.81. The MoBa questionnaire concerning
father's health, including if he had type 1 diabetes or not,
was not available for this study.
Sociodemographic characteristics of the participants
Sociodemographic characteristics from the MoBa ques-
tionnaires that were used to describe the sample were
maternal income and maternal education. Maternal age
at delivery and marital status were abstracted from the
records of the MBRN.
Child's genetic risk
A child's genetic risk was based directly on the results
from the genotyping in the MIDIA study. The value of the
variable was set to 1 if the mother had a newborn with
high genetic risk for type 1 diabetes, and 0 if the mothers
had a newborn without high genetic risk.
Statistical analysis
Handling of missing data in SCL-8, RSES, and SWLS
The MVA (EM) imputation procedure in SPSS 14.0 was
used to impute missing values for each construct item
using the remaining construct items as predictors. Data
from respondents with more than four values of SCL8
missing from the eight items in total were excluded from
the analyses. Data from respondents with more than two
values of SWLS missing from the five items in total were
excluded from the analyses. Data from respondents with
more than one value of RSES missing from the four items
were excluded from the analyses.
The imputation of the SCL-8 items increased the sam-
ple with valid data from 6994 subjects (complete data on
all eight SCL-8 items) to 7349 subjects at the 30th week of
pregnancy and from 6726 to 7361 subjects when the
infant was 6 months old, whereas the number of subjects
with valid data on both occasions increased from 6487 to
7321. Corresponding values for SWLS were 7277 subjects
before and 7346 subjects after imputation (30th week of
pregnancy), 7237 before and 7308 after (when the infant
was 6 months old), and 7134 before and 7266 after (valid
data on both occasions). Valid RSES data increased from
7301 subjects to 7339 subjects (30th week of pregnancy),
from 7298 to 7345 (when the infant was 6 months old),
and from 7215 to 7296 subjects (valid data on both occa-
sions).
Regression analysis
Regression analysis included answers from mothers with
valid data at both baseline (the 30th week questionnaire)
and after the disclosure of genetic risk (6 months ques-
tionnaire). Linear regression analyses were conducted
separately for the dependent variables:
1. Symptoms of anxiety and depression (SCL-8)
2. Self-esteem (RSES)
3. Subjective well-being (SWLS).
In each of the three analyses, the dependent variable
was the post-disclosure score for the maternal mental
health variable. The independent variables were: child's
genetic risk, maternal type 1 diabetes, and the baseline
score for the maternal mental health variable. Exposure
to risk information was the principal explanatory vari-
able. By including the mental health baseline score as an
independent variable, the effect of the independent vari-
ables can be interpreted as the effect in terms of a change
in mental health from baseline to post-disclosure. V ari-
ables that are often chosen as covariates in multivariate
analyses, such as demographic factors, are likely to be dis-
tributed by chance between the genetic high-risk and
non-high-risk groups. As expected, preliminary bivariate
tests showed no relationship between genetic risk and theAas et al. BMC Medical Genetics 2010, 11:112
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demographic variables and, accordingly, demographic
variables were not included in the analysis. However,
maternal type 1 diabetes co-varies with the child's genetic
risk and was entered as a covariate.
Logistic regression analysis was conducted with mater-
nal worry about the child as a dependent variable. No
baseline measurement was available for this dichotomous
variable. Child's genetic risk and maternal type 1 diabetes
were entered as predictors.
All analyses were conducted using SPSS, version 14.02.
Results
Subjects
There were no significant differences between the two
study groups (Table 1) on the sociodemographic variables
maternal education, marital status, maternal income, or
maternal age (p > 0.27, chi-square tests). Thus, the socio-
demographic variables were not included in the multivar-
iate analyses.
Comparisons with National data indicate that married
or cohabitating mothers were over-represented in the
study cohort (participants: 96.7%; national data: 89.6%)
[34]. Furthermore, women with a college or university
education were over-represented in the cohort (partici-
pants: 61.1%; national data: 36.1%) [35]. National data
indicate that the mean maternal age when giving birth is
30.2 years [36], which is only slightly different from the
present study group (mean 30.4, SD 4.4).
Effects of genetic risk information on maternal mental 
health measures
The results from the linear regression analyses of the
association between genetic risk information and change
in maternal mental health are shown as unstandardized
(B) and standardized (β) coefficients in Table 2. The
upper part of Table 2 shows the results from the regres-
sion analysis with symptoms of anxiety and depression
(SCL) as the dependent variable. The estimated regres-
sion coefficient (B = -0.001, p = 0.95) for child's genetic
risk indicated no effect of genetic information on changes
in maternal mental health from baseline to post-disclo-
sure. The maternal type 1 diabetes status also had no
effect (B = 0.040, p = 0.409). However, as expected, the
baseline anxiety/depression score was strongly associated
with post-disclosure scores (B = 0.536, p < 0.001).
The middle and the lower part of Table 2 show similar
negative results for the analysis of RSES and SWLS
scores.
Effects of genetic risk information on maternal worry about 
the child
Logistic regression was conducted with the mother's
report on whether she felt seriously worried about her
child (0 = no, 1 = yes) as a dependent variable. Maternal
worry was measured in the 6 months questionnaire. Of
the 7309 valid answers (excluding 81 participants who did
not answer this question), 1227 mothers had felt serious
worry about their child. Logistic regression revealed no
difference between the mothers of high-risk and non-
high-risk children (OR = 0.98, 95% CI 0.64-1.48, p = 0.91).
An increased risk of maternal worry was seen if the
mother herself had type 1 diabetes (OR = 2.39, 95% CI
1.20-4.78, p = 0.01).
Discussion
T his  st u dy c om par ed m e n ta l hea l t h m eas ur es  bet w ee n
mothers who received genetic risk information about
their child and a control group. The results show no asso-
ciation between maternal notification of the results from
predictive genetic testing of newborns for type 1 diabetes
and maternal symptoms of anxiety and depression, satis-
faction with life, self-esteem, or serious worry about the
child.
Our study design is strong in some respects. The par-
ticipants were from the MoBa study, a national prospec-
tive pregnancy cohort in which some of the mothers also
participated in genetic testing of their newborns for
HLA-conferred susceptibility for type 1 diabetes as part
of the MIDIA study. Unlike most studies on the effect of
testing newborns for a genetic risk of type 1 diabetes [20-
24], the responses were given in a "neutral context": that
is, the MoBa study did not have a specific purpose of
studying the effects of genetic risk, so the mothers were
not prompted to mentally focus on what they were sup-
posed to report or what the researchers might expect
them to report about the effects of such painful informa-
tion. The study sample consisted of 166 mothers of chil-
dren with the high-risk genotype and a control group of
7224 mothers of children not carrying the high-risk geno-
type for type 1 diabetes. These large sample sizes provide
adequate power for detecting differences between the
two groups of mothers. The mental health measurements
were reported both before and after receiving the infor-
mation about genetic risk, providing the opportunity to
adjust for baseline measurements in the analysis. Finally,
consistency of the findings across three different vali-
dated measures of mental health strengthens the conclu-
sion that mental health was not reduced by
communicating genetic risk.
Previous studies examining the psychological reactions
of mothers of children with high genetic risk for type 1
diabetes found no significant effect on anxiety or other
serious mental health symptoms in the group as a whole
in response to genetic risk information [20-24]. The pres-
ent study confirmed the main results from previous stud-
ies. The contribution from our study is associated with an
absence of context effects, large sample sizes, and avail-
able baseline scores. Weaknesses in previous studies wereAas et al. BMC Medical Genetics 2010, 11:112
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Table 1: Sociodemographic characteristics of included study participants (N = 166 for high-risk group and N = 7224 for 
non-high-risk group)
High-risk group Non-high-risk group
No. of subjects Percentage 95% CI No. of subjects Percentage 95% CI
N* % N* %
Maternal Education
Primary school (9 years) 0 0 0 132 1.8 1.5 - 2.1
Secondary school (10-13 years) 56 33.8 26.5 - 40.9 2236 30.9 29.9 - 32.0
College/University (≤ 4 years) 71 42.8 35.2 - 50.3 2984 41.3 40.2 - 42.5
College/University (> 4 years) 24 14.5 9.1 - 19.8 1464 20.3 19.3 - 21.2
Marital status
Married 88 53 45.4 - 60.6 3703 51.3 50.1 - 52.4
Living together 67 40.4 32.9 - 47.8 3290 45.5 44.4 - 46.7
Divorced/Single/Other 5 3 0.4 - 5.6 162 2.2 1.9 - 2.6
Maternal income**
< 200.000 NOK 51 30.8 23.7 - 37.7 1888 26.2 25.1 - 27.2
200.000-300.000 NOK 56 33.7 26.5 - 40.9 2683 37.1 36.0 - 38.3
300.000-400.000 NOK 37 22.3 16 - 28.6 1627 22.5 21.6 - 23.5
> 400.000 NOK 10 6 2.4 - 9.6 783 10.9 10.1 - 11.6
Maternal age at delivery
< 25 years 15 9 4.7 - 13.4 648 9 8.3 - 9.6
25-34 years 121 72.9 66.1 - 79.7 5268 72.9 71.9 - 73.9
> 34 years 27 16.3 10.7 - 21.9 1265 17.5 16.6 - 18.4
Maternal type 1 diabetes 1 0.6 0 - 1. 8 36 0.5 0.3 - 0.7
* Because of missing data, not all numbers fits with the total number of participants ** NOK = Norwegian Krone
small sample sizes [22,24], lack of baseline measures
[20,21,23], or no control group [20,21]. In some previous
studies, effects of genetic risk information were revealed
when the mothers were asked questions relating directly
to the test results [22,23]. One week after obtaining the
risk information, 55% of the mothers surveyed by Simo-
nen et al. expressed modest worry about the test results
[23]. In addition, Kerruish et al. reported higher levels of
concern about the child's genetic risk status among moth-
ers of high-risk children compared to low-risk children
[22]. Because the questions in the present study were
taken from questionnaires intended to study health and
well-being in general, specific questions about concern
about the genetic test results were not included, and
therefore cannot be compared with these previous stud-
ies.
A weakness of the present study is the time lag between
exposure to the risk information and observation of men-
tal health. The MoBa 6 month questionnaire was distrib-
uted 3 to 3.5 months after information about risk was
provided. Review studies investigating the effects of pre-
dictive genetic testing on adults have indicated that, over
time, risk perception decreases [37], and test results were
rarely predictive of distress more than one month after
testing [38]. On the other hand, the MIDIA follow-up
package, which is an obvious reminder about the child's
risk, is sent to the parents around 2 weeks before com-
pleting the 6 months questionnaire. Overall, one cannot
exclude that a difference between the mothers of high-
risk and non-high-risk children would have been
detected if maternal psychological health had been
assessed closer to the time that the risk information was
provided.
The parents of high-risk and non-high-risk children
received risk information and counselling to a different
extent. During the period after testing, the children withAas et al. BMC Medical Genetics 2010, 11:112
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type 1 diabetes were subject to follow-up, including the
opportunity for the parents to consult the project physi-
cian and health nurses at any time. The follow-up also
included biological monitoring of blood samples to mea-
sure autoantibody levels, thus increasing the possibility of
early diagnosis and a less severe onset of the disease if the
child were to develop type 1 diabetes. If the mothers of
high-risk children had been left by themselves after
receiving the risk information, we cannot exclude some
deterioration of maternal mental health.
Information about a child's seroconvertion is expected
to lead to increased anxiety in the mothers, as this is a
strong indicator of increased risk for development of type
1 diabetes [39]. However, none of the children serocon-
verted at the 3 months follow-up.
The findings of this study are not necessarily fully valid
for genetic screening. In screening, all newborns would
be enrolled for genetic testing, whereas in a prospective
cohort study, participants decide, after careful consider-
ation, if they want to participate in the study and receive
the results. This may have led to self-selection of individ-
uals who believe themselves to be fit to handle risk infor-
mation. This assumption was supported in a recent study
[40], which found that adults who anticipated having
adverse psychological reactions to genetic testing were
less likely to choose genetic testing. Likewise, Codori et
al. compared a group who had chosen predictive testing
for Huntington's disease and a group who had chosen not
to be tested [41]. The conclusion was that the tested
group anticipated problems with emotional reactions less
often and expected to be able to cope with such reactions
should they appear. Furthermore, Decruyenaere et al.
found that the individuals who tested themselves for
Huntington's disease had higher ego strength and were
more socially extroverted than the general population
[42].
One of the limitations of quantitative studies such as
ours is the inability to acknowledge and be fully aware of
"single case destinies", small number of mothers who
might react very strongly to genetic risk information
about their child. Although the present study does not
show an association between predictive genetic testing
and maternal mental health, previous studies have shown
that such information could be a burden to a few individ-
uals [20,21,23]. Hood et al. found that although depres-
sive symptom scores are not elevated for the group as a
whole, there is considerable variety in the responses [20].
Mothers with ethnic minority status, low education, and
p o s t - p a r t u m  d e p r e s s i o n  s e e m  t o  b e  m o r e  l i k e l y  t o
respond to risk notification with depressive symptoms.
Similarly, Johnson et al. found that ethnic minority status,
low education, and not being married are associated with
elevated anxiety levels [21].
Mothers who have type 1 diabetes seemed to worry
more about their child. The mothers from the group with
not-high-risk children who expressed worry would be
responding to something other than the gene test. The
mothers could still worry about their child getting the
disease, or another chronic disease.
Conclusions
This study did not find evidence supporting the notion
that genetic risk information about newborns has a nega-
tive impact on the mental health of Norwegian mothers.
Table 2: Effects of maternal diabetes and genetic risk information on mental health variables
B (95% CI) βp Adjusted R2
Symptoms of anxiety and depression
Child's genetic risk -0.001 (-0.047 - 0.044) -0.001 0.953
Maternal type 1 diabetes 0.040 (-0.055 - 0.135) 0.008 0.409
Baseline anxiety/depression 0.536 (0.517 - 0.555) 0.544 < 0.001
0.296
Self esteem
Child's genetic risk 0.037 (-0.022 - 0.097) 0.011 0.218
Maternal type 1 diabetes -0.040 (-0.164 - 0.083) -0.006 0.521
Baseline self esteem 0.682 (0.664 - 0.700) 0.651 < 0.001
0.423
Satisfaction with life scale
Child's genetic risk -0.080 (-0.198 - 0.039) -0.013 0.187
Maternal type 1 diabetes 0.016 (-0.231 - 0.263) 0.001 0.902
Baseline SWLS 0.609 (0.590 - 0.628) 0.587 < 0.001
0.345Aas et al. BMC Medical Genetics 2010, 11:112
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